Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

By Lemin Zheng, Benedicta N. Nukuna, M. Brennan, Mingjiang Sun, M. Goormastic, Megan Settle, D. Schmitt, Xiaoming Fu, L. Thomson, P. Fox and 4 more. Journal of Clinical Investigation, 2004

744 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Immunology, Physiology

View Paper: https://www.semanticscholar.org/paper/f3e662b3521ff83327ae16026f742e203331f1ce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Chapman
2. A. Kontush
3. J. Keaney

In Physiology

1. K. Sugamura
2. J. Keaney

Citations in the corpus

• Reactive Oxygen Species in Cardiovascular Disease (2011, background): “Apolipoprotein A-I (Apo A-I), the major protein component of HDL, contains a specific binding site for MPO [159, 160].”
• Biomarkers of oxidative damage in human disease. (2006, neutral): “Multiple sclerosis (24) Cardiovascular disease (125)”
• Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, background): “Oxidized amino acid residues, including chlorotyrosines, nitrotyrosines and oxidized lysine and methionine residues, are present in apoA-I isolated from plasma and from human atherosclerotic lesions (Bergt et al., 2004; Zheng et al., 2004; Panzenbock and Stocker, 2005; Shao et al., 2005c); furthermo”
• HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms (2011, background): “In one study, preβ-1-HDL levels were actually higher in patients with ischemic heart disease than in normal individuals, and the activity of LCAT in these patients was diminished”